New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
08:13 EDTRHHBY, VRTXVertex flu treatment may become large franchise, says William Blair
After Vertex (VRTX) reported data for its flu treatment, William Blair believes that the data appears promising and superior in some ways to Roche's (RHHBY) Tamiflu, a multibillion dollar franchise. The firm doesn't think the Street has assigned any value to Vertex's flu treatment, and it maintains an Outperform rating on the stock.
News For VRTX;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
18:42 EDTVRTXOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTVRTXVertex expects FY14 revenues $525M-$535M, consensus $551.82M
Subscribe for More Information
16:18 EDTVRTXVertex reports Q3 adjusted EPS (37c), consensus (62c)
Subscribe for More Information
11:14 EDTRHHBYRoche unit announces collaboration pact with ImmunoGen
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with ImmunoGen (IMGN) to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha, or FRa, that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate.
October 27, 2014
20:54 EDTRHHBYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:20 EDTRHHBYAmerican Association of Blood Banks to hold annual meeting
Subscribe for More Information
October 24, 2014
12:03 EDTRHHBYRoche reports CHMP recommends label update for Esbriet
Subscribe for More Information
October 22, 2014
05:37 EDTVRTXVertex approval could add 500 more patients, says Piper Jaffray
Subscribe for More Information
October 21, 2014
16:49 EDTVRTXVertex: FDA Advisory Committee recommends approval of KALYDECO
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administrationís Pulmonary Allergy Drugs Advisory Committee voted 13-2 to recommend approval of KALYDECO in people with cystic fibrosis ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory gene, which is the indication being reviewed by the FDA.
15:25 EDTVRTXPanel backs approval for Vertex CF drug in R117H mutation, Bloomberg says
Subscribe for More Information
15:18 EDTVRTXPanel votes Vertex CF drug safe, works for R117H mutation, Bloomberg reports
Subscribe for More Information
07:15 EDTRHHBYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:11 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committe to hold a meeting
Subscribe for More Information
October 20, 2014
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTRHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use